Chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative disorders display familial aggregation. To identify a susceptibility gene for CLL we assembled families from the major European (ICLLC) and American (GEC) consortia to conduct a genome-wide linkage analysis of 101 new CLL pedigrees using a high-density single nucleotide polymorphism (SNP) array and combined the results with data from our previously reported analysis of 105 families. Here we report on the combined analysis of the 206 families. Multipoint linkage analyses were undertaken using both non-parametric (model-free) and parametric (model-based) methods. After the removal of high linkage disequilibrium SNPs we obtained a maximum NPL of 3.02 (P= 1.3 x 10 -3 ) on chromosome 2q21.2. The same genomic position also yielded the highest multipoint heterogeneity LOD (HLOD) score under a common recessive model of disease susceptibility (HLOD = 3.11;
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INTRODUCTION

B-cell chronic lymphocytic leukemia (CLL [MIM #151400]) accounts for ~25% of all leukemia and is
the most common form of lymphoid malignancy in Western countries 1 . Family [2] [3] [4] and epidemiological studies [5] [6] [7] [8] [9] The striking multiple-case families reported in the literature provide substantive evidence for an inherited predisposition to CLL [2] [3] [4] and suggest the existence of susceptibility alleles with pleiotropic effects 2, 10 . Case-control and cohort studies that have systematically estimated the familial risk of CLL and other LPDs have shown that most B-cell LPDs display site-specific elevated familial risks [5] [6] [7] [8] [9] , but particularly CLL, where risks are increased 3 to 7-fold in first-degree relatives of cases. array, which contained ~11,500 single nucleotide polymorphisms (SNPs) 12 . In both studies analyses provided evidence for susceptibility at a number of loci, but none achieved statistical significance suggesting that a much larger familial sample was required to identify CLL predisposition loci.
To address this we have undertaken a further genome-wide linkage scan of an additional 101 families ascertained through the International CLL Consortium (ICLLC) and the Genetic Epidemiology of CLL (GEC) consortia. This search was conducted using high-density SNP arrays thereby allowing us to pool findings with data generated from our previous scan of 105 families and in so creating a dataset of 206 families, representing the vast majority of CLL families identified in worldwide. Here we report further evidence for a Mendelian predisposition to CLL and strong evidence for the location of novel disease loci.
METHODS
Ascertainment and collection of families
For clarity we refer to our previously reported genome-wide scan of 105 pedigrees reported 12 as
Phase 1 and the current analysis of 101 pedigrees as Phase 2. As for Phase 1, Phase 2 pedigrees consisted of families with B-cell CLL with or without the segregation of additional B-Cell LPD cases. These families were ascertained through hematologists in the United Kingdom, United
States, Norway, Israel, Italy, Germany, Netherlands, Portugal and Australia participating in the ICLLC (51 Phase 2 families) and the GEC consortia (50 Phase 2 families). The diagnoses of B-cell CLL and other B-cell LPDs in affected family members were established using accepted standard clinico-pathological and immunological criteria in accordance with current WHO classification guidelines 13 . Blood samples were obtained from both the offspring and spouse of deceased affected family members wherever possible to facilitate the reconstruction of genotypes. DNA was extracted from venous blood samples using conventional methodologies. Research protocols and informed consents were obtained according to each group's institutional review board.
Genotyping
Prior to genotyping all DNA samples were quantified by PicoGreen (Invitrogen, Paisley, UK used to obtain raw microarray feature intensities. Feature intensities were processed using Affymetrix GTYPE (v4.0) software to derive SNP genotypes (Affymetrix Inc., Santa Clara, CA).
Data manipulation and error checking
The Phase 1 genome-wide linkage scan had been undertaken using the GeneChip 
Investigation of linkage disequilibrium
Most linkage software for multipoint analyses assumes that markers are in linkage equilibrium.
However, for closely spaced SNP markers this is not always the case. To identify markers in high linkage disequilibrium (LD), we calculated the pair-wise LD measure r 2 between consecutive pairs of SNP markers using the expectation-maximization algorithm to estimate two-locus haplotype frequencies as previously described 12 . A pair of SNPs was defined as being in high-LD if they had a pair-wise LD measure of r 2 >0.16 in accordance with criteria recently advocated 16 . Linkage disequilibrium was then removed by considering each set of markers in LD (defined as sets where each consecutive marker pair in the set had r 2 >0.16) and retaining one SNP from each set (the centrally positioned SNP). The impact of LD was investigated by considering linkage results calculated before and after the removal of the high-LD SNPs.
Linkage analysis
Multipoint linkage analysis was conducted by implementation of the Perl script SNPLINK 17 , which performs fully automated non-parametric (mode-of-inheritance free) and parametric analyses before and after LD removal using the program ALLEGRO (v1.2) 18 . Although primary statistical analyses were based on NPL scores, parametric linkage in the presence of heterogeneity was assessed using heterogeneity LOD (HLOD) scores and their accompanying estimates of the proportion of linked families (α) estimated. These analyses require the specification of a diseasetransmission model. We derived LOD scores under both dominant and recessive models of inheritance with reduced penetrance and two age categories dependent upon age at diagnosis (<65 and 65+ years). In the absence of a genetic model we adopted a pragmatic approach to this analysis choosing values that were consistent with the population age-specific risks of CLL and compatible with the range of familial risks. The lifetime risk (defined at age 84 years) for being diagnosed with CLL in the US population using the SEER registry data is estimated to be ~0.37% 19 . We assumed an allele frequency of either 0.005 or 0.05 under the dominant models, and 0.05 and 0.20 under the recessive models. In order to satisfy the constraints of the lifetime risk and familial relative risks, for the dominant models the penetrance of the rare and common alleles were assumed to be 4.2% and 2.8% for individuals aged less than 65 and 9.0% and 6.0% for those over 64 years. For the recessive models penetrances of the rare and common alleles were assumed to be 14.0% and 7.0%, and 30.0% and 15.0% respectively for the two liability classes. To allow for phenocopies, the penetrance of the normal genotypes under all models was set to 0.14% and 0.3%, respectively. All unaffected individuals were considered uninformative (i.e., of unknown phenotype) in the analysis.
Heterogeneity LOD scores follow a complex statistical distribution, which can be approximated by the maximum of two independently distributed were then derived, using the χ 2 distribution with one degree of freedom. The nominal p value for the HLOD score is then given by:
Results are reported in terms of an NPL statistic and its associated one-sided p value. Under the null hypothesis of no linkage, the NPL statistic is distributed asymptotically as a standard normal random variable. An estimate of the information content (IC) for each chromosome before and after high LD SNP removal was determined by use of marker set entropy information derived by Merlin 21 .
RESULTS
Description of families analyzed
The 206 families included in Phase 1 (n=105) and Phase 2 (n=101) comprised 155 CLL families and 51 families segregating CLL and other B-cell LPDs (Table 1) . Within the 206 families there were 487 individuals affected with CLL and 63 individuals affected with NHL or HL. A higher proportion of families in Phase 2 were multi-generational compared with those in Phase 1 ( Table   1 ). The difference in composition of families between the two Phases is not a consequence of predefined criterion for ascertainment of families, but is reflective in part of a consequence of the ongoing development of ICLLC and GEC. Overall 42% of the 206 families contained three or more affected individuals.
The median age at diagnosis of CLL in the 206 families was 60 years, significantly less than the median value of 72 years for age at diagnosis observed in the general white population 19 . Minimum age at diagnosis within a family is likely to be a superior indicator of the potential for existence of a susceptibility gene, since it is not influenced by older sporadic cases. In our families, the minimum age of diagnosis within the families ranged from 28 years to 81 years with a median value of 56 years.
Within Phase 1 203/238 (85%) family members affected with CLL were genotyped together with 17/22 (77%) of those affected with LPD and 3 unaffected individuals. In Phase 2 families 101/249 (41%) individuals affected with CLL and 22/41 (54%) of those affected with LPD were genotyped.
In addition 51 unaffected family members were typed primarily in order to reconstruct genotypes of unavailable affected family members.
Data quality
In addition to the 223 Affymetrix 10K131 arrays run and used in the Phase1 analyses, a total of 171 Affymetrix 10Kv2.0 arrays were processed in Phase 2. A number of parameters were employed throughout the study to determine data quality and all genotypes were housed within the pedigree storage program ProgenyLab. The average SNP call rate per array for Phase 2 was 98.0% compared to 92.8% for Phase 1. For DNA extracted from males, it was possible to examine the 309 markers on the X chromosome for errors due to miscalls or PCR contamination. No SNPs were heterozygous in male samples. Two hundred and seventy three markers were fixed or were without a single map location leaving 9,933 usable SNPs (97.3%), of which 9,690 mapped to autosomes. After LD removal 7,495/9,690 markers remained (77.4%). Less than 0.4% of the total SNP genotypes generated were considered unlikely by ProgenyLab and/or Merlin. All such genotypes were removed from further analyses.
Linkage analysis
The IC derived for the Phase 1 analyses from using only the 10,204 SNPs contained within the Figure 2 shows transformed multipoint HLOD scores (-log 10 (P-value) generated using the most parsimonious dominant and recessive models and (Tables 2 and 3 , Figure 2 ). For each of the regions there was limited evidence that linkage was primarily generated by any specific families.
For chromosome 6 the best fitting model was attained imposing a common recessive allele with 72% of families being linked, respectively; again with support coming from both Phases ( Table 2) .
HLODs for Phase1 and Phase 2 were 1.35 and 1.22 respectively. For chromosomes 5 and 11 the best fitting model was attained imposing a rare recessive allele with 85% and 82% of families being linked, respectively (Tables 2 and 3) . Support for chromosome 5 linkage was not biased to either Phase 1 or Phase 2, but the region at which maximal linkage was attained was inconsistent.
Similarly for chromosome 11 the majority of the support for linkage came from Phase 1 data (NPL= 2.66, P= 3.9 x 10 -3 ) and maximal linkage obtained at different chromosomal locations (Table   2 ). In contrast for chromosome 18q21.1 the best fitting model was attained imposing a rare dominant allele with 68% of families being linked, most of the evidence coming from Phase 2 data (NPL= 2.81, P= 2.5 x 10 -3 ).
Restricting the analysis to affection status solely defined by CLL (n = 182 families) made no significant difference to the overall linkage statistics attained at 2q21.2, 5q23.2, 6p22.1, 11q12.1 and 18q21.1 (Tables 2 and 3 ).
DISCUSSION
Following publication of two previous linkage studies that failed to identify significant linkage, we combined the extant families from diverse institutions worldwide, and two existing consortia, to generate the largest collection of familial CLL to date.
Our results provide evidence for a major susceptibility locus on chromosome 2 influencing the risk of CLL -with characteristics consistent with an autosomal recessive model of inheritance. We did not find any significant evidence for linkage in the combined dataset to any of the regions of the genome commonly associated with cytogenetically detectable chromosomal losses (6q, 13q14, or 17p) or gains (trisomy 12) in CLL [25] [26] [27] . In addition to linkage to 2q21.2 we found evidence of a recessively acting locus for CLL mapping to 6p22.1 and a dominantly acting locus mapping to 18q21.1 on the basis of presumptive Mendelian models of predisposition.
Here we have made use of data generated from high-density SNP arrays to search for CLL predisposition loci by linkage. In addition to affording maximal power to detect linkage the output from such arrays permits pooling of data from different scans to be efficiently conducted avoiding the serious problems of microsatellite-based searches. The combined dataset of 206 families has permitted us to robustly identify a novel locus on chromosome 2 which had only displayed linkage at the 1% level in our previous search. Furthermore, we have increased evidence for linkage to While there is no definitive consensus on the thresholds to be used to manage the issue of LD between SNPs we excluded SNPs with high LD, defined as those with a pair-wise linkage disequilibrium measure r 2 > 0. 16 . This can be viewed as conservative but is a threshold for triaging SNPs in high LD which has been recently recommended 16 . When we originally reported analysis of the first 105 families 12 we imposed a less stringent criterion, advocated at the time of r 2 > 0.40 28 .
Given that high LD between SNP markers impacts on linkage statistics but does not result in loss of information content within our dataset we strongly endorse imposing stringent thresholds when using high-density arrays for linkage analyses.
Although speculative at this juncture, several interesting candidate genes involved in aspects of the regulation of cellular proliferation and differentiation of B-cells map to the regions of linkage on 2q21 and 18q21. The region identified on chromosome 2 includes the chemokine receptor gene (CXCR4) whose expression is higher in CLL cells and which is thought to be associated with disease progression 29 . Levels of CXCR4 have also been associated with Rai stage 30 and with survival in familial CLL 31 . CXCR4 germline mutations are responsible for the warts, hypogammaglobulinemia, infections, and myelokathexis syndrome (WHIM; MIM #193670). The chromosome 18 region contains the SMAD7 gene (mothers against decapentaplegic, drosophila, homolog of, 7; MIM #602932) whose expression has been implicated in growth arrest and apoptosis of B lineage cells and Ig class switching [32] [33] [34] . It is also intriguing that we found support for involvement of the MHC region by virtue of linkage at 6p22.1. A support for HLA alleles in the development of B-cell LPD is provided by the observation of linkage in sibships with Hodgkin's lymphoma 35 and some previous association studies have also implicated variants within or close to the MHC class II region in susceptibility to CLL 36 .
Reduced expression of death associated protein kinase 1 (DAPK1) through epigenetic silencing by promoter methylation and histone tail modification has been reported to occur in the majority of sporadic CLL cases. A rare, single-nucleotide germline mutation (c.1-6531A>G) upstream of DAPK1 which maps to 9q21.33, has recently been reported to segregate with CLL in a large family suggesting that heritable predisposition to CLL may in part be mediated through germline variation in DAPK1 37 . The contribution of inherited mutations in DAPK1 to familial risk is unclear, however, in our analyses we found no evidence of linkage to this region of 9q21 (either in the complete dataset or in a restricted analysis based on only larger pedigrees with affection status solely defined by CLL and with four or more affected individuals) suggesting the contribution of this locus to the overall familial aggregation of the disease is small.
Our results suggest that more than one gene is contributing to risk of CLL in families. Such loci could be epistatic or acting independently. The observation of sub-clinical levels of monoclonal Bcell lymphocytosis (MBL) with an identical phenotype to indolent CLL detectable in 3% of healthy individuals but 14% of first-degree relatives in high-risk CLL families 38 suggests this phenotype is a marker of genetic risk and may be an early event in the oncogenic process, consistent with a model based on epistatic interaction. As only a paucity of individuals from the 206 pedigrees have been tested for this phenotype it was not possible to make use of MBL status in our current analysis. Future mapping studies of high risk families incorporating data on MBL status on all available family members are therefore desirable to better characterize the model.
In conclusion, follow-up of linkage signals on 2q21, 18q21, and 6p22 is warranted along with screening of individuals for presence of the MBL phenotype. In conjunction with conventional fine mapping of loci, as has been shown for DAPK1 37 it may be possible to also make use of expression data to identify novel disease genes. This should be possible through the on-going collection of families from ICLLC and GEC consortia, as well as available population-based casecontrol collections. 
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